Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Inclusion Criteria

• •Participants must be ≥ 18 years of age
• •Able to understand and give written informed consent
• •Confirmation of small cell neuroendocrine prostate cancer (SCNPC) diagnosis by internal pathology review of initial or subsequent biopsy or other pathologic material at Fred Hutchinson Cancer Center/University of Washington
• •Previously treated with a platinum-based chemotherapy regimen for SCNPC
• •Participants may not have received prior therapy or plan to receive therapy (chemotherapy, immunotherapy and/or radiation therapy) or have undergone or plan to undergo major surgery within the last 3 weeks prior to leukapheresis AND initiation of lymphodepleting chemotherapy. Participants who have developed SCNPC in the context of prior androgen deprivation therapy (ADT) (i.e. medical/surgical castration) may continue on ADT at the discretion of their treating provider
• •Evidence of L1CAM positivity by immunohistochemistry review of the patient's archival/fresh tumor samples
• •Metastatic or locally advanced and unresectable disease
• •Adequate performance status (Eastern Cooperative Oncology Group \[ECOG\] 0 or 1)
• •Expected survival \> 3 months
• •Fertile participants must be willing to use an effective contraceptive method before, during, and for at least 4 months after the CAR T cell infusion
• •Measurable disease per RECIST v1.1 criteria as determined by CT, MRI or positron emission tomography (PET) scan
• •Hemoglobin \> 9 g/dL (prior to leukapheresis)
• •Absolute neutrophil count (ANC) \> 1,500 per mm\^3 (prior to leukapheresis)
• •Platelets \> 100,000 per mm\^3 (prior to leukapheresis)
• •Creatinine ≤ 1.5 x upper limit of normal (ULN) (prior to leukapheresis)
• •Bilirubin ≤ 1.5 x ULN (≤ 3 x ULN in patients with known Gilbert's syndrome) (prior to leukapheresis)
• •Aspartate transaminase (AST) ≤ 3.0 x ULN (prior to leukapheresis)
• •Alanine transaminase (ALT) ≤ 3.0 x ULN (prior to leukapheresis)
• •Alkaline phosphatase ≤ 3.0 x ULN (prior to leukapheresis)
• •All prior treatment related toxicity prior to leukapheresis ≤ grade 2 by National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version (v) 5.0
• •Known history of unstable angina or myocardial infarction (MI) within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy
• •New York Heart Association (NYHA) class III or IV congestive heart failure (CHF), clinically significant hypotension, uncontrolled symptomatic coronary artery disease, or a documented ejection fraction of \< 35%
• •Known history of clinically significant active chronic obstructive pulmonary disease (COPD), or other moderate-to-severe chronic respiratory illness present within 6 months
• •Participants with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing. Those with an forced expiratory volume (FEV1) of \< 50 % of predicted or diffusing capacity for carbon monoxide (DLCO) (corrected) \< 40% will be excluded. Patients with \> grade 1 dyspnea at rest or oxygen saturation \< 94% on room air (resting)
• •Infection requiring intravenous antibiotic use within 2 weeks of leukapheresis or uncontrolled active infection
• •Baseline serum sodium level \< 130 mEq/L
• •Research participant is not receiving systemically administered steroid therapy. Physiologic glucocorticoid replacement therapy for management of adrenal insufficiency is allowed (≤ 10 mg daily of prednisone or equivalent)
• •History of an autoimmune disease requiring immunosuppressant therapy within the past 5 years
• •Other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations
• •Known history of brain metastases.
• •* Note: Brain imaging is not required to determine eligibility. However, this should be performed if there is clinical suspicion for brain metastases